Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients
Joint Authors
Tap, William D.
Sofocleous, Constantinos T.
D’Angelo, S. P.
Ziv, Etay
Erinjeri, Joseph P.
Sutton, Charles
Zhang, Yachao
Kim, DaeHee
Yarmohammadi, Hooman
Boas, Franz E.
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-02-15
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
One way to enhance quality of life for patients with metastatic sarcoma is to maximize time off chemotherapy—a chemotherapy-free interval.
While image-guided ablation of sarcoma metastases may reduce the need for chemotherapy, it remains unknown how long ablation could extend the chemotherapy-free interval.
The purpose of our study was to determine the chemotherapy-free interval in comparison to overall survival and progression-free survival in sarcoma patients who undergo ablation procedures.
An IRB-approved, single institution, HIPAA compliant database was queried for sarcoma patients who underwent image-guided ablation procedures between 2007 and 2018.
Patient demographics, histologic subtype, and other clinical characteristics were recorded.
Kaplan-Meier analysis was performed to compute median overall survival, median progression-free survival (local and distant), and the median chemotherapy-free interval (systemic and cytotoxic) after ablation.
Univariate and multivariate analyses were performed using the log-rank test and Cox proportional-hazards model, respectively.
A total of 100 sarcoma patients were included in the analysis.
The most common histologic subtype was leiomyosarcoma (38%).
Median overall survival after ablation of sarcoma metastases was 52.4 months (95% CI: 46.9–64.0 months).
The median systemic chemotherapy-free interval following ablation of sarcoma metastases was 14.7 months (95% CI: 8.6–34.3 months).
The median cytotoxic chemotherapy-free interval following ablation of sarcoma metastases was 81.3 months (95% CI: 34.3-median not reached).
In conclusion, ablation of sarcoma metastases can provide an extended systemic chemotherapy-free interval of greater than 1 year.
Ablation of sarcoma metastases may improve patient quality of life by extending the chemotherapy-free interval.
American Psychological Association (APA)
Sutton, Charles& Zhang, Yachao& Kim, DaeHee& Yarmohammadi, Hooman& Ziv, Etay& Boas, Franz E.…[et al.]. 2020. Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Complexity،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1207310
Modern Language Association (MLA)
Zhang, Yachao…[et al.]. Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Complexity No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1207310
American Medical Association (AMA)
Sutton, Charles& Zhang, Yachao& Kim, DaeHee& Yarmohammadi, Hooman& Ziv, Etay& Boas, Franz E.…[et al.]. Analysis of the Chemotherapy-Free Interval following Image-Guided Ablation in Sarcoma Patients. Complexity. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1207310
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1207310